Drugs / Verekitug
Verekitug
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05653479 | Dec 2022 → Apr 2023 | — | Upstream Bio Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05448651 | Jul 2022 → Aug 2023 | asthma | Upstream Bio Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06981078 | Jul 2025 → Oct 2027 expected | chronic obstructive pulmonary disease | Upstream Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06966479 | May 2025 → Sep 2027 expected | asthma | Upstream Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06196879 | Feb 2024 → Dec 2025 | asthma | Upstream Bio Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06164704 | Dec 2023 → Jul 2025 | chronic rhinosinusitis | Upstream Bio Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verekitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06164704 ↗ |
| Known as | ASP-7266 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315002 ↗ |
| Known as | Formerly ASP7266 | “Formerly ASP7266” NCT05448651 ↗ |
| Known as | UPB-101 | “Verekitug (UPB-101) formulated solution” NCT06196879 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5315002 ↗ |
| Route | Subcutaneous | “administered subcutaneously (SC)” NCT05448651 ↗ |